Simcere Pharmaceutical Group (NYSE:SCR)

CAPS Rating: 2 out of 5

The Company is a manufacturer and supplier of branded generic pharmaceuticals in the fast growing China market.

Results 1 - 20 of 24 : 1 2 Next »

Recs

0
Member Avatar Calinvestments (96.94) Submitted: 5/13/2011 1:32:36 PM : Outperform Start Price: $12.39 SCR Score: -62.82

This is a small/mid cap high growth stock that should outperform the S&P during the bull market.

Recs

0
Member Avatar value18 (< 20) Submitted: 10/9/2009 7:15:07 PM : Outperform Start Price: $7.44 SCR Score: -42.37

china GROWTH

Recs

0
Member Avatar oxdeming (55.23) Submitted: 8/12/2009 11:41:52 PM : Outperform Start Price: $8.53 SCR Score: -73.91

low valuation; great beneficiary of health reform in China; government strong support; cost-effectiveness in rolling out innovative medicine; leading performer in Chinese pharm sector

Recs

0
Member Avatar sante06 (53.65) Submitted: 7/25/2009 1:31:06 PM : Outperform Start Price: $8.71 SCR Score: -82.64

Generics will dominate the drug industry in this Social Communist country.

Recs

0
Member Avatar wallstreetweapon (< 20) Submitted: 7/15/2009 10:55:44 AM : Outperform Start Price: $8.19 SCR Score: -86.74

Solid balance sheet. Look to buy below $9

Recs

0
Member Avatar tkaikobad (< 20) Submitted: 5/23/2009 12:34:31 PM : Underperform Start Price: $6.35 SCR Score: +63.72

to much volatility

Recs

0
Member Avatar manetheren86 (29.25) Submitted: 4/15/2009 12:30:37 PM : Outperform Start Price: $6.66 SCR Score: -80.58

On the rise...

Recs

0
Member Avatar Trimalerus (92.82) Submitted: 4/3/2009 4:38:55 AM : Outperform Start Price: $5.72 SCR Score: -59.56

China is paying the price for their rapid industrial growth in high rates of Cancer and Lung Disease related to the air pollution. China is trying to shift to a green energy model, but in the meantime they have a lot of sick people needing cheap medicines, which this company manufactures. Stock is currently near 52 week low, with loads of upward growth potential in their market. Good long term buy in my opinion.

Recs

0
Member Avatar Ibeatmykids (80.10) Submitted: 3/29/2009 2:42:31 PM : Outperform Start Price: $5.60 SCR Score: -66.68

generic Rx company in China. Obama with his healthcare reform. America's love to solve problems by taking a pill. Very cheap. I can't pass it up.

Recs

0
Member Avatar CrazyCal17 (83.16) Submitted: 8/1/2008 1:01:01 PM : Outperform Start Price: $12.29 SCR Score: -76.01

This stock is a great choice. By evaluating this company and looking at their growth pattern and their marketing strategies this is a sure fire stock to pick. This company has great leadership with the ability to think outside the box. With the possibility of some future acquisitions this has all the ingredients for wonderful success, short term and long term both. Keep up and watch out. With this outlook ahead, we should also look to the left and right (aka their competion) for huge leaps as well. If you have a little on the side I say diversify within the sector and buy from all the competetors too for they also are looking very solid. That is my pick and I am sticking to it.

Recs

0
Member Avatar agchris02 (< 20) Submitted: 7/22/2008 5:59:48 PM : Outperform Start Price: $11.90 SCR Score: -70.93

This is a play I may change in a few months, as I'm not sure on their long term potential. However, with the earnings coming out August 5, and everything I can read screams that they will meet, or exceed, their estimated earnings, this appears to be a great short term play.

With its current financial strength (assets/liabilities > 6:1), high Net profit margin, and good sales of the core products, the chances of a significant decline is small, particularly given the fact that its near a 52-week low DESPITE earnings having grown more than 80% over the past year. Go figure, earnings grow 80%, sign three new contracts for generic drug distribution, record cash comes in, stock price declines 40%. With more research (to be done this weekend), I may extend my time frame to several years. I'll update as necessary.

Recs

0
Member Avatar Sqwii (< 20) Submitted: 6/4/2008 4:11:38 PM : Outperform Start Price: $15.01 SCR Score: -76.47

Bullish signal stocksabroad

Recs

0
Member Avatar Boone12 (< 20) Submitted: 6/3/2008 12:15:14 PM : Outperform Start Price: $14.40 SCR Score: -73.15

With the price of the stocks for this company there is still intrest in what it can do for the country.

Recs

0
Member Avatar hanlerris (47.17) Submitted: 4/10/2008 8:24:54 AM : Outperform Start Price: $11.10 SCR Score: -57.43

Way undervalued for a strong growth potential that this company shows.

Recs

0
Member Avatar jchallis (< 20) Submitted: 4/6/2008 9:30:33 PM : Outperform Start Price: $11.50 SCR Score: -57.81

Sustainable competitive advantage.

Recs

0
Member Avatar vtraja (89.46) Submitted: 4/1/2008 12:40:28 PM : Outperform Start Price: $10.93 SCR Score: -55.97

Simcere has a lot of scope for growth and it is selling at a reasonable P/E currently. At worst it shouldn't lose value but in two years or so I expect it would double in value especially in a growing economy like China where healthcare is getting increasing attention.

Recs

0
Member Avatar ESCalanderAI (36.51) Submitted: 3/3/2008 7:38:26 AM : Outperform Start Price: $10.56 SCR Score: -56.16

EXP POS EARN

Recs

0
Member Avatar nexboogie (< 20) Submitted: 2/29/2008 2:33:15 PM : Outperform Start Price: $10.50 SCR Score: -55.17

Why be bullish on a little known Chinese pharma company with an overheated Chinese market due for more correction? Because bottom line they are making drugs. Not just some designer drugs, they make generics(one slice of drug mkt), they have anti-cancer drugs(huge growth upside), they are buying or partnering with other companies who have products to distribute.

They are positioning themselves for huge upside.

Now for the bearish end, it just listed as an ADR in April 07, has been trending downward since, as of my choosing this they haven't announced 4Q 07 earnings yet. There seems to be a problem with newly listed Chinese ADRs at times, murky information, hopefully they will learn to put more news out there. So this could guide lower temporarily if earnings are missed (approx .12), If it beats then it is a great sign towards future growth and entrenchment into the Chinese pharma industry.

Very thinly traded right now so any big stake is going to move it, as yet only 13% Institutional owners.

Recs

0
Member Avatar JjcampNR (72.18) Submitted: 1/14/2008 12:52:04 AM : Outperform Start Price: $13.25 SCR Score: -66.27

High risk? Yes. Company in an already inflated China market? Yes.

Taking those things into consideration I think the upside potential here is absolutely huge. Generic drugs with a market as large as the population of China...I think it's worth the risk.

Recs

0
Member Avatar lareineivre (89.21) Submitted: 12/30/2007 2:48:23 AM : Outperform Start Price: $13.18 SCR Score: -60.28

Favorable risk / reward profile. Comparative analysis:
http://f1.grp.yahoofs.com/v1/8EF3R8IApDlbI1SUEwj9ACPoO-N506V3BymU7tTVdt21_4PxNLCn-oJ6KY_K8iQ5Z-yn652fM-b9S1MpHcVrFg/VOps/VOps%2007.11.30.xls

Results 1 - 20 of 24 : 1 2 Next »

Featured Broker Partners


Advertisement